Cargando…
The 150 most important questions in cancer research and clinical oncology series: Questions 25–30: Edited by Chinese Journal of Cancer
To accelerate our endeavors to overcome cancer, Chinese Journal of Cancer has launched a program of publishing 150 most important questions in cancer research and clinical oncology. In this article, 6 more questions are presented as followed. Question 25: Does imprinting of immune responses to infec...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418677/ https://www.ncbi.nlm.nih.gov/pubmed/28472999 http://dx.doi.org/10.1186/s40880-017-0210-y |
_version_ | 1783234086907674624 |
---|---|
collection | PubMed |
description | To accelerate our endeavors to overcome cancer, Chinese Journal of Cancer has launched a program of publishing 150 most important questions in cancer research and clinical oncology. In this article, 6 more questions are presented as followed. Question 25: Does imprinting of immune responses to infections early in life predict future risk of childhood and adult cancers? Question 26: How to induce homogeneous tumor antigen expression in a heterogeneous tumor mass to enhance the efficacy of cancer immunotherapy? Question 27: Could we enhance the therapeutic effects of immunotherapy by targeting multiple tumor antigens simultaneously or sequentially? Question 28: Can immuno-targeting to cytokines halt cancer metastasis? Question 29: How can we dynamically and less-invasively monitor the activity of CD8(+) T killer cells at tumor sites and draining lymph nodes? Question 30: How can the immune system destroy the niches for cancer initiation? |
format | Online Article Text |
id | pubmed-5418677 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-54186772017-05-08 The 150 most important questions in cancer research and clinical oncology series: Questions 25–30: Edited by Chinese Journal of Cancer Chin J Cancer Editorial To accelerate our endeavors to overcome cancer, Chinese Journal of Cancer has launched a program of publishing 150 most important questions in cancer research and clinical oncology. In this article, 6 more questions are presented as followed. Question 25: Does imprinting of immune responses to infections early in life predict future risk of childhood and adult cancers? Question 26: How to induce homogeneous tumor antigen expression in a heterogeneous tumor mass to enhance the efficacy of cancer immunotherapy? Question 27: Could we enhance the therapeutic effects of immunotherapy by targeting multiple tumor antigens simultaneously or sequentially? Question 28: Can immuno-targeting to cytokines halt cancer metastasis? Question 29: How can we dynamically and less-invasively monitor the activity of CD8(+) T killer cells at tumor sites and draining lymph nodes? Question 30: How can the immune system destroy the niches for cancer initiation? BioMed Central 2017-05-04 /pmc/articles/PMC5418677/ /pubmed/28472999 http://dx.doi.org/10.1186/s40880-017-0210-y Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Editorial The 150 most important questions in cancer research and clinical oncology series: Questions 25–30: Edited by Chinese Journal of Cancer |
title | The 150 most important questions in cancer research and clinical oncology series: Questions 25–30: Edited by Chinese Journal of Cancer |
title_full | The 150 most important questions in cancer research and clinical oncology series: Questions 25–30: Edited by Chinese Journal of Cancer |
title_fullStr | The 150 most important questions in cancer research and clinical oncology series: Questions 25–30: Edited by Chinese Journal of Cancer |
title_full_unstemmed | The 150 most important questions in cancer research and clinical oncology series: Questions 25–30: Edited by Chinese Journal of Cancer |
title_short | The 150 most important questions in cancer research and clinical oncology series: Questions 25–30: Edited by Chinese Journal of Cancer |
title_sort | 150 most important questions in cancer research and clinical oncology series: questions 25–30: edited by chinese journal of cancer |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418677/ https://www.ncbi.nlm.nih.gov/pubmed/28472999 http://dx.doi.org/10.1186/s40880-017-0210-y |
work_keys_str_mv | AT the150mostimportantquestionsincancerresearchandclinicaloncologyseriesquestions2530editedbychinesejournalofcancer AT 150mostimportantquestionsincancerresearchandclinicaloncologyseriesquestions2530editedbychinesejournalofcancer |